Advertisement

Hormone Therapy in Breast and Prostate Cancer

  • V. Craig Jordan
  • Barrington J.A. Furr

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages I-XVI
  2. An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer

    1. Front Matter
      Pages 1-1
  3. Preclinical Antiestrogens

    1. Front Matter
      Pages 15-15
    2. Colin K. W. Watts, Owen W. J. Prall, Jason S. Carroll, Nicholas R. C. Wilcken, Eileen M. Rogan, Elizabeth A. Musgrove et al.
      Pages 17-45
    3. Ruth M. O’Regan, Anait S. Levenson, Gale M. England, Kathy A. Yao, Henry D. Muenzner, Hiroyuki Takei et al.
      Pages 47-68
    4. Alan E. Wakeling
      Pages 161-181
  4. Antiestrogens: Clinical

    1. Front Matter
      Pages 183-183
    2. V. Craig Jordan
      Pages 185-193
    3. Ruth M. O’Regan, William J. Gradishar
      Pages 195-212
    4. Monica Morrow, V. Craig Jordan
      Pages 213-231
  5. Inhibition of Estrogen Synthesis

    1. Front Matter
      Pages 233-233
    2. Paul E. Goss, Caroline C. Reid
      Pages 235-263
    3. K. Shenton, Mitchell Dowsett, Michael Dukes
      Pages 265-291
  6. Androgens and Androgen Withdrawal

    1. Front Matter
      Pages 309-309
    2. Shutsung Liao, Junichi Fukuchi, Yung-Hsi Kao
      Pages 311-324
    3. Fritz H. Schröder, Albert Radlmaier
      Pages 325-346
    4. Geert J. C. M. Kolvenbag, Barrington J.A. Furr
      Pages 347-368
    5. Amir V. Kaisary
      Pages 369-382
  7. Perspective on Progress

    1. Front Matter
      Pages 383-383
    2. V. Craig Jordan, Barrington J.A. Furr
      Pages 385-408
  8. Back Matter
    Pages 409-420

About this book

Introduction

Millions of people are now successfully using hormone antagonists for the treatment of endocrine-dependent cancers. In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying these targeted treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed-antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen, raloxifene, and others), and such antiandrogenic strategies as goserelin and bicalutamide.
Unique in its synthesis, Hormone Therapy in Breast and Prostate Cancer offers medical and surgical oncologists, urologists, physicians, and clinical pharmacologists a sound basis for understanding targeted treatments of breast and prostate cancers, and provides a well-proven model for developing powerful new cancer therapeutics.

Keywords

Drogen cancer cancer prevention cancer research carcinogenesis cell drug drug resistance hormones liver prevention prostate cancer research resistance steroids

Editors and affiliations

  • V. Craig Jordan
    • 1
  • Barrington J.A. Furr
    • 2
  1. 1.Lombardi Comprehensive Cancer CenterGeorgetown UniversityWashingtonUSA
  2. 2.AstraZeneca Pharmaceuticals Zeneca PharmaceuticalMacclesfieldUK

Bibliographic information

Industry Sectors
Pharma
Health & Hospitals
Biotechnology